InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,412.40
(
0.05%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.84
(
1.12%
)
Bitcoin
64,929.34
(
-2.37%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cushsix

Send PM Follow Ignore
Followers 1
Posts 97
Boards Moderated 0
Alias Born 03/24/2009

cushsix

Re: None

Monday, 10/22/2012 10:53:08 AM

Monday, October 22, 2012 10:53:08 AM

Post# of 80490
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA):

Stifel Nicolaus surveyed 35 hematology/oncology specialists, and the firm now believes that the survey indicates that ARIAD’s ponatinib in front-line CML showed significant potential. The firm believes that the company’s outlook for the drug’s selling continues to be conservative, and it keeps its Buy rating on the stock.

GLA
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up